Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Novo Nordisk revealed a stunning increase in pollution amid plans to boost production of its popular weight loss drug Wegovy.